DE60325695D1 - Der eaat2-promotor und dessen verwendung - Google Patents

Der eaat2-promotor und dessen verwendung

Info

Publication number
DE60325695D1
DE60325695D1 DE60325695T DE60325695T DE60325695D1 DE 60325695 D1 DE60325695 D1 DE 60325695D1 DE 60325695 T DE60325695 T DE 60325695T DE 60325695 T DE60325695 T DE 60325695T DE 60325695 D1 DE60325695 D1 DE 60325695D1
Authority
DE
Germany
Prior art keywords
eaat2 promoter
eaat2
promoter
modulate
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60325695T
Other languages
German (de)
English (en)
Inventor
Jeffrey D Rothstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE60325695D1 publication Critical patent/DE60325695D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
DE60325695T 2002-02-15 2003-02-14 Der eaat2-promotor und dessen verwendung Expired - Fee Related DE60325695D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35717902P 2002-02-15 2002-02-15
PCT/US2003/004414 WO2003070965A2 (en) 2002-02-15 2003-02-14 The eaat2 promoter and uses thereof

Publications (1)

Publication Number Publication Date
DE60325695D1 true DE60325695D1 (de) 2009-02-26

Family

ID=27757583

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325695T Expired - Fee Related DE60325695D1 (de) 2002-02-15 2003-02-14 Der eaat2-promotor und dessen verwendung

Country Status (7)

Country Link
US (1) US7723505B2 (https=)
EP (1) EP1474434B1 (https=)
JP (1) JP2005517449A (https=)
AT (1) ATE420176T1 (https=)
AU (1) AU2003211040A1 (https=)
DE (1) DE60325695D1 (https=)
WO (1) WO2003070965A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540288A (en) * 2002-11-22 2009-06-26 Univ Johns Hopkins Target for therapy of cognitive impairment
US20040171108A1 (en) * 2003-02-07 2004-09-02 Fisher Paul B. Human excitatory amino acid transporter-2 gene promoter and uses thereof
AU2004214938B2 (en) * 2003-02-26 2008-11-06 Johns Hopkins University Glutamate transport modulatory compounds and methods
AU2004285473A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
JP2005333845A (ja) * 2004-05-25 2005-12-08 Tokyoto Igaku Kenkyu Kiko ミトコンドリア局在型ＤｓＲｅｄ２及びＥＣＦＰ発現ベクター
JP4586149B2 (ja) * 2007-09-10 2010-11-24 長瀬産業株式会社 プロモーターおよびその活性化方法
US9719146B2 (en) * 2009-09-09 2017-08-01 General Electric Company Composition and method for imaging stem cells
CN111956658B (zh) * 2020-07-28 2023-04-28 中国医学科学院医药生物技术研究所 miRNA 148簇作为诊断和/或治疗认知障碍相关疾病标志物的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
US7060457B2 (en) * 1998-03-18 2006-06-13 Johns Hopkins University Aberrant glutamate transporters and methods of use
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040171108A1 (en) 2003-02-07 2004-09-02 Fisher Paul B. Human excitatory amino acid transporter-2 gene promoter and uses thereof

Also Published As

Publication number Publication date
JP2005517449A (ja) 2005-06-16
AU2003211040A8 (en) 2003-09-09
US7723505B2 (en) 2010-05-25
WO2003070965A8 (en) 2004-04-22
WO2003070965A3 (en) 2004-03-18
EP1474434B1 (en) 2009-01-07
WO2003070965A9 (en) 2004-07-15
US20050048488A1 (en) 2005-03-03
EP1474434A4 (en) 2006-07-26
ATE420176T1 (de) 2009-01-15
WO2003070965A2 (en) 2003-08-28
AU2003211040A1 (en) 2003-09-09
EP1474434A2 (en) 2004-11-10

Similar Documents

Publication Publication Date Title
MY146548A (en) Certain chemicals entities, compositions, and methods
MXPA06012613A (es) Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
ATE421589T1 (de) Optisches abbildungssystem zur darstellung der genexpression des gesamten körpers und anwendungen
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
DE60325695D1 (de) Der eaat2-promotor und dessen verwendung
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
NO20065768L (no) Karbonsamid-opioidforbindelser
WO2010017240A3 (en) Aurora kinase modulators and methods of use
IS7021A (is) Nýjar heteróarýlafleiður, framleiðsla þeirra og notkun
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
MXPA05011157A (es) Nuevo metodo para modular la actividad relacionada a los huesos.
DE60327543D1 (de) Substituierte tetraline und indane und ihre verwendung
EP1532446A4 (en) LIGANDS OF G-PROTEIN-COUPLED RECEPTORS AND METHODS
DE602006018461D1 (de) Galk1s als modifikatoren des pten/akt-wegs
ATE403665T1 (de) Verfahren und zusammensetzungen zur modulierung der gluconeogenese mit pgc-1
MXPA03011766A (es) Novedosos derivados de indol.
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
WO2007056056A3 (en) Mitotic kinesin inhibitors
ATE469175T1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren
DE602005013805D1 (de) Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee